Q1-FY26 · Hitesh Windlas
Our business is more amenable to be evaluated on longer-term basis rather than quarter by quarter and also as a whole rather than part by part.
WINDLAS / language trends
Read confidence between the lines.
Windlas Biotech · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q1-FY26 · Hitesh Windlas
We don't want to say that we are not giving guidance and then give guidance. The right thing is to look at our past performance in the last 10 quarters and our aspiration is always to better things.
Q1-FY26 · KumL Gupta
Injectable gross margins are higher... if you look at some pure injectable CDMO players, they are somewhere in the range of 18% to 21%. Potentially at least 10% of our revenue could be at 10-20% in that region once we execute.
Q3-FY26 · Dr. Hitesh Windlas
We have delivered 12 consecutive quarters of highest ever revenue. We want to surprise you pleasantly – that is the intent and that is the effort.
Q3-FY26 · Kumal Gupta
Schedule M compliance is not just about capital access to capital. It is about knowhow, talent, and systems. This is where having multinational clients has benefited Windlas because these clients have been working with us – we get almost 70 to 80 audits a year.
Q3-FY26 · Kumal Gupta
In exports, results are binary or time-bound. We might be at 70% and then we get to know this is not working out, and there are others which we don't expect and they happen earlier than expected.